NCT03009162View on ClinicalTrials.gov

Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

June 2, 2017

Study Completion Date

June 2, 2017

Conditions

Migraine

Interventions

DRUG

Lasmiditan

200 mg, single oral tablet

Trial Locations (2)

H3P3P1

CIUSSS de l'est-de-l'île-de-Montréal - installation Hôpital Maisonneuve-Rosemont, Montreal

Algorithme Pharma, Mount Royal

Sponsors

Collaborators (1)

CoLucid Pharmaceuticals

All Listed Sponsors

collaborator

CoLucid Pharmaceuticals

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT03009162 - Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function | Biotech Hunter | Biotech Hunter